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Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS
mutations in exon 2 do not benefit from anti-epidermal growth factor receptor
(EGFR) therapy. Other activating RAS mutations may also be negative predictive
biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective
analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin,
fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone,
according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639
patients who had metastatic colorectal cancer without KRAS mutations in exon
2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2,
3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was
90%. RESULTS: Among 512 patients without RAS mutations, progression-free
survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with
FOLFOX4 alone (hazard ratio for progression or death with combination therapy,
0.72; 95%...
Document type : Article de périodique (Journal article)
Référence bibliographique
Douillard, Jean-Yves ; Oliner, Kelly S ; Siena, Salvatore ; Tabernero, Josep ; Burkes, Ronald ; et.
al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. In: New England
Journal of Medicine, Vol. 369, no.11, p. 1023-1034 (2013)
DOI : 10.1056/NEJMoa1305275
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;11 nejm.org september 12, 2013 1023
original article
Panitumumab–FOLFOX4 Treatment  
and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., 
Josep Tabernero, M.D., Ronald Burkes, M.D., Mario Barugel, M.D.,  
Yves Humblet, M.D., Ph.D., Gyorgy Bodoky, M.D., Ph.D.,  
David Cunningham, M.D., Jacek Jassem, M.D., Ph.D., Fernando Rivera, M.D., Ph.D., 
Ilona Kocákova, M.D., Ph.D., Paul Ruff, M.D., Maria Błasińska-Morawiec, M.D., 
Martin Šmakal, M.D., Jean Luc Canon, M.D., Mark Rother, M.D.,  
Richard Williams, M.B., B.S., Ph.D., Alan Rong, Ph.D., Jeffrey Wiezorek, M.D., 
Roger Sidhu, M.D., and Scott D. Patterson, Ph.D.
From Institut de Cancérologie de l’Ouest 
(ICO) René Gauducheau, Nantes, France 
(J.-Y.D.); Amgen, Thousand Oaks, CA 
(K.S.O., R.W., A.R., J.W., R.S., S.D.P.); Os-
pedale Niguarda Ca’ Granda, Milan (S.S.); 
Vall d’Hebron University Hospital, Univer-
sitat Autònoma de Barcelona, Barcelona 
(J.T.), and Hospital Universitario Marqués 
de Valdecilla, Santander (F.R.) — both in 
Spain; Mount Sinai Hospital, Toronto (R.B.), 
and Credit Valley Hospital, Mississauga, 
ON (M.R.) — both in Canada; Hospital de 
Gastroenterología, Buenos Aires (M.B.); 
Université Catholique de Louvain, Brussels 
(Y.H.), and Grand Hôpital de Charleroi, 
Charleroi ( J.L.C.) — both in Belgium; 
Szent László Hospital, Budapest, Hungary 
(G.B.); Royal Marsden National Health 
Service Foundation Trust, London (D.C.); 
Medical University of Gdansk, Gdansk 
(J.J.), and Copernicus Memorial Hospital, 
Lodz (M.B.-M.) — both in Poland; Ma-
saryk Memorial Cancer Institute, Brno 
(I.K.), and Institute of Oncology and Reha-
bilitation Pleší, Nová Ves pod Pleší (M.Š.) 
— both in the Czech Republic; and the 
University of the Witwatersrand Faculty 
of Health Sciences, Johannesburg (P.R.). 
Address reprint requests to Dr. Douillard 
at ICO René Gauducheau, Blvd. Jacques 
Monod, 44805 Saint Herblain, France, or 
at jean-yves.douillard@ico.unicancer.fr.
Drs. Douillard and Oliner contributed equal-
ly to this article.
N Engl J Med 2013;369:1023-34.
DOI: 10.1056/NEJMoa1305275
Copyright © 2013 Massachusetts Medical Society.
A BS TR AC T
Background
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not 
benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating 
RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy.
Methods
In this prospective–retrospective analysis, we assessed the efficacy and safety of pani-
tumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with 
FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 
639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 
had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; 
or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%.
Results
Among 512 patients without RAS mutations, progression-free survival was 10.1 months 
with panitumumab–FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for 
progression or death with combination therapy, 0.72; 95% confidence interval [CI], 
0.58 to 0.90; P = 0.004). Overall survival was 26.0 months in the panitumumab–
FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for 
death, 0.78; 95% CI, 0.62 to 0.99; P = 0.04). A total of 108 patients (17%) with non-
mutated KRAS exon 2 had other RAS mutations. These mutations were associated 
with inferior progression-free survival and overall survival with panitumumab–
FOLFOX4 treatment, which was consistent with the findings in patients with KRAS 
mutations in exon 2. BRAF mutations were a negative prognostic factor. No new 
safety signals were identified.
Conclusions
Additional RAS mutations predicted a lack of response in patients who received 
pani tumumab–FOLFOX4. In patients who had metastatic colorectal cancer with-
out RAS mutations, improvements in overall survival were observed with panitum-
umab–FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov 
number, NCT00364013.)
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K RAS mutation is an established pre-dictive biomarker of resistance to anti–epidermal growth factor receptor (EGFR) 
therapy in patients with metastatic colorectal 
cancer.1-4 Specifically, patients with KRAS muta-
tions in exon 2 do not have a response to anti-
EGFR therapy and may have inferior outcomes if 
this therapy is combined with an oxaliplatin-con-
taining chemotherapy regimen.2,5 More accurate 
selection of patients according to the genetic sta-
tus of the tumor may improve the benefit–risk 
profile of anti-EGFR therapy.
Activating mutations in RAS (KRAS or NRAS) 
in addition to KRAS mutations in exon 2 have been 
suggested as negative predictive biomarkers for 
anti-EGFR therapy. This is biologically plausible 
on the basis of the existing biochemical and 
mutational data. KRAS and NRAS are closely re-
lated RAS oncogene family members, and muta-
tions in either gene at codons 12, 13, 61, 117, 
and 146 result in increased levels of guanosine 
triphosphate–bound RAS proteins.6,7 In addition, 
colorectal tumors harbor KRAS and NRAS muta-
tions at these codons, and mutations tend to be 
mutually exclusive; this suggests functional redun-
dancy.8 Mutations in HRAS, the third member of 
the RAS family, occur infrequently in colorectal 
cancer.8,9
Clinical data have also implicated RAS genes 
as negative predictive biomarkers. In a randomized 
phase 3 study of panitumumab monotherapy10 and 
other studies,11-15 most patients with metastatic 
colorectal-cancer tumors harboring a mutation 
in KRAS or NRAS did not have a response to 
anti-EGFR therapy.
BRAF mutations are typically exclusive of RAS 
mutations, and the clinical data suggest that 
the BRAF V600E mutation is prognostic of pa-
tient outcome with respect to survival, but not 
clearly predictive of treatment effects with anti-
EGFR agents, in patients with metastatic colorec-
tal cancer.16-19 Although no objective responses 
to panitumumab or cetuximab monotherapy 
have been reported in patients with metastatic 
colorectal cancer and BRAF mutations,10,20 the 
low prevalence of such mutations makes it dif-
ficult to evaluate them as predictive biomarkers.
Previous studies of anti-EGFR therapies com-
bined with oxaliplatin-containing regimens have 
shown negative outcomes in subgroups of pa-
tients with KRAS mutations in exon 2. Identifica-
tion of other biomarker-defined subgroups with 
similar outcomes would influence the choice of 
therapy.2,5 Here, we present the results of a pro-
spective–retrospective biomarker analysis of the 
treatment effect of the full spectrum of cur-
rently characterized RAS (KRAS and NRAS) and 
BRAF mutations on progression-free survival and 
overall survival in a randomized phase 3 study 
of panitumumab plus oxaliplatin, f luorouracil, 
and leucovorin (FOLFOX4) as compared with 
FOLFOX4 alone in patients with previously un-
treated metastatic colorectal cancer.
Me thods
Study Design and Oversight
The Panitumumab Randomized Trial in Combina-
tion with Chemotherapy for Metastatic Colorectal 
Cancer to Determine Efficacy (PRIME) compared 
the efficacy and safety of panitumumab–FOLFOX4 
with those of FOLFOX4 alone in the first-line 
treatment of patients, according to KRAS exon 2 
status. The primary end point was progression-
free survival. The secondary end points included 
overall survival and safety.2
The study was designed by the sponsor, Amgen, 
in collaboration with the first author and the study 
steering committee. Clinical data were collected 
by the investigators, and sequencing analysis was 
conducted by Transgenomic under the direction 
of the sponsor. The sponsor performed all statis-
tical analyses. All authors vouch for the accuracy 
of the data and analyses and for the fidelity of 
this report to the protocol, which is available 
with the full text of this article at NEJM.org. The 
preliminary draft of the manuscript was written 
by the second author with the assistance of a 
medical writer who was paid by the sponsor. 
Subsequent drafts were revised and reviewed by 
all the authors. All the authors made the deci-
sion to submit the manuscript for publication.
Tumor Specimens
Banked tumor specimens that were character-
ized as nonmutated KRAS exon 2 on the basis of 
an assay for investigational use only (TheraScreen 
KRAS Mutation Kit, Qiagen; LightCycler, Roche) 
were selected for analysis.2 DNA was extracted 
from formalin-fixed, paraffin-embedded tumor 
specimens with the use of a DNA Extraction 
Mini Kit (Qiagen). Specimens that contained 
less than 50% tumor area were macrodissected. 
In a few cases, DNA was extracted from stored 
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slides that had been stained for immunohisto-
chemical analysis.
Mutational Analysis
Mutations in KRAS exon 3 (at codon 61) and 
exon 4 (at codons 117 and 146); NRAS exon 2 (at 
codons 12 and 13), exon 3 (at codon 61), and 
exon 4 (at codons 117 and 146); and BRAF exon 15 
(at codon 600) were prespecified on the basis of 
previous studies.7,14,21,22 Gene alterations that 
were not prespecified (e.g., KRAS and NRAS exon 3 
[codon 59] mutations) were analyzed as explor-
atory end points. Polymerase-chain-reaction (PCR) 
primer sequences amplified regions up to 200 bp 
in length to account for the fragmented nature of 
DNA in formalin-fixed, paraffin-embedded speci-
mens. Separate data sets were generated by means 
of bidirectional Sanger sequencing and WAVE-
based Surveyor Scan Kits (Transgenomic).23-26 
Double-stranded PCR amplicons were melted 
and cooled to form a heteroduplex–homoduplex 
mixture that was treated with Surveyor nuclease. 
The resulting DNA fragments were analyzed with 
the use of high-performance liquid chroma-
tography (WAVE HS System). The formation of 
mutant:nonmutant heteroduplexes resulted in frag-
ments of various sizes. The testing plan and meth-
ods were prespecified, and investigators in the 
testing laboratory were unaware of treatment as-
signments and clinical outcomes. Bidirectional 
Sanger sequencing and testing with WAVE-based 
Surveyor Scan Kits were validated according to 
the Clinical Laboratory Improvement Amendments 
of 1988.
Statistical Analysis
The statistical analysis plan was prespecified be-
fore the RAS and BRAF testing results became 
available. Two clinical data snapshots were used: 
the primary analysis (prespecified to be performed 
when >50% of patients with nonmutated KRAS 
exon 2 had died from any cause) and the updated 
analysis of overall survival (an exploratory analy-
sis that was undertaken when >80% of patients in 
both the nonmutated and mutated KRAS exon 2 
subgroups had died from any cause), which pro-
vided the most up-to-date estimate of overall sur-
vival in the PRIME study.
The primary objective of the current prospec-
tive–retrospective analysis was to evaluate the treat-
ment effect of panitumumab–FOLFOX4 as com-
pared with FOLFOX4 alone in patients without 
RAS mutations (nonmutated KRAS and NRAS 
exons 2, 3, and 4) and in those without RAS and 
BRAF mutations (nonmutated KRAS and NRAS 
exons 2, 3, and 4, and BRAF exon 15) in the 
primary-analysis population of the PRIME study. 
Subsequent evaluation of the treatment effect on 
the basis of the updated overall-survival data was 
similarly prespecified in the statistical analysis 
plan, but only the results of the overall-survival 
end point are reported, since data collection was 
limited to survival information. Patients were 
characterized as having RAS mutations if any 
predefined activating mutation in KRAS or NRAS 
was detected, and patients were characterized as 
having RAS or BRAF mutations if any predefined 
RAS or BRAF mutation was detected.
The hypothesis testing in this analysis was 
exploratory in nature. An overall 5% significance 
level was used to compare the treatment effect 
on progression-free survival and overall survival 
in subpopulations without RAS mutations and in 
subpopulations without RAS and BRAF mutations. 
To control the overall type 1 error rate, a sequential 
testing scheme was used for evaluation of the 
treatment effects of panitumumab on progression-
free survival among patients with nonmutated RAS 
and nonmutated RAS and BRAF, followed by a 
test of the treatment effects on overall survival 
among patients in the same subgroups. No hypoth-
esis testing was conducted in the subgroups with 
mutations. To estimate the treatment effects of 
panitumumab, we used Cox proportional-hazards 
models stratified according to randomization fac-
tors, with all randomly assigned patients in each 
biomarker subgroup included in the assessment. 
A log-rank test stratified according to randomiza-
tion factors was used to compare the treatment 
effects on progression-free survival and overall 
survival in the panitumumab–FOLFOX4 group 
with the treatment effects on progression-free 
survival and overall survival in the FOLFOX4-alone 
group. Sensitivity analyses, including a multivari-
ate Cox model and propensity-score analysis, were 
used to confirm the primary results. Interaction 
tests were performed to compare the treatment 
effects of panitumumab between the subgroup 
with nonmutated RAS and the subgroup with 
mutated RAS and between the subgroup with non-
mutated RAS and the subgroup with nonmutated 
KRAS in exon 2 and other RAS mutations. Multi-
variate Cox models were also used to explore the 
prognostic relevance of baseline covariates.
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R esult s
Patients
Of the 1183 patients who underwent randomiza-
tion, 1096 (93%) had previously been evaluated 
for KRAS exon 2 (656 patients without KRAS mu-
tations in exon 2 [60%] and 440 patients with 
KRAS mutations in exon 2 [40%]) (Fig. S1 in the 
Supplementary Appendix, available at NEJM.org).2 
The status of KRAS exon 3 or 4; NRAS exon 2, 3, 
or 4; or BRAF exon 15 (Table 1, and Table S1 in 
the Supplementary Appendix) was determined in 
639 of the 656 patients without KRAS mutations 
in exon 2. Identical results were obtained by 
means of bidirectional Sanger sequencing and 
WAVE-based Surveyor analysis.
RAS status was ascertained in 1060 of the 
1183 patients (90%) who underwent random-
ization. Of these 1060 patients, 512 (48%) were 
identified as having tumors with nonmutated 
RAS (no KRAS or NRAS mutations in exons 2, 3, 
or 4) and 548 (52%) were identified as having 
tumors with mutated RAS (any KRAS or NRAS 
mutations in exon 2, 3, or 4) (Fig. S1 in the Sup-
plementary Appendix). Of 620 patients with data 
that could be evaluated for RAS, 108 (17%) who 
were originally categorized as not having KRAS 
mutations in exon 2 had other RAS mutations. 
Baseline clinical and demographic characteris-
tics, including race or ethnic group, age, Eastern 
Cooperative Oncology Group (ECOG) performance-
status score (on a scale from 0 to 5, with 0 indi-
cating no symptoms and full activity and higher 
scores indicating increasing levels of disability),27 
primary tumor type, and number of metastatic 
lesions were generally similar between patients 
with nonmutated RAS and those with mutated 
RAS and were consistent with the reported re-
sults for KRAS exon 2 in patients with meta-
static colorectal-cancer tumors.2
The rate of ascertainment of RAS and BRAF 
status was 89% (assessed in 1047 of 1183 pa-
tients). Of 619 patients without KRAS mutations 
in exon 2 who could be evaluated for BRAF, 53 (9%) 
had V600E mutations. Mutations in BRAF exon 15 
were mutually exclusive of KRAS and NRAS muta-
tions in patients without KRAS mutations in exon 2 
who could be evaluated. The proportion of pa-
tients with each of the RAS or BRAF mutations 
(Table 1) was consistent with that reported in a 
recently published article.21
Efficacy According to Tumor RAS Status
At the time of the primary analysis (data-cutoff 
point, August 29, 2009), 54% of the patients had 
died.2 In patients without KRAS mutations in 
exon 2 who received panitumumab–FOLFOX4, 
as compared with those who received FOLFOX4 
alone, there was a significant improvement in pro-
gression-free survival (9.6 vs. 8.0 months, P = 0.02) 
and a 4.2-month improvement in overall survival, 
which was not significant (23.9 vs. 19.7 months, 
P = 0.07) (Table 2). In an exploratory, updated anal-
ysis of overall survival (data-cutoff point, Janu-
ary 24, 2013), 82% of the patients had died. On the 
basis of this analysis, panitumumab–FOLFOX4 
was associated with a 4.4-month improvement in 
overall survival (23.8 months in the panitumumab–
FOLFOX4 group vs. 19.4 months in the FOLFOX4-
alone group, P = 0.03).
These analyses were extended to evaluate the 
predictive value of mutations other than KRAS 
mutations in exon 2. In the subgroup of patients 
without RAS mutations (the primary-analysis pop-
ulation), panitumumab–FOLFOX4, as compared 
with FOLFOX4 alone, was associated with a 
significant improvement in progression-free 
survival (10.1 vs. 7.9 months, P = 0.004) and a 
significant 5.8-month improvement in overall 
survival (26.0 vs. 20.2 months, P = 0.04) (Table 2 
and Fig. 1 and 2A and 2B). Consistently, signifi-
cant results were observed in the exploratory, 
updated overall-survival analysis with respect to 
the magnitude of improvement with panitumu-
mab–FOLFOX4 as compared with FOLFOX4 alone 
(Table 2 and Fig. 2C).
A total of 17% of patients without KRAS mu-
tations in exon 2 had mutations in other RAS 
exons. In this subgroup of 108 patients, out-
comes in the primary analysis and in the explor-
atory updated analysis of overall survival showed 
that progression-free survival (Fig. S2A in the 
Supplementary Appendix) and overall survival 
(Fig. S2B and S2C in the Supplementary Appen-
dix) were shorter in the panitumumab–FOLFOX4 
group than in the FOLFOX4-alone group, though 
the difference was not significant. These out-
comes were consistent with those observed in 
the subgroup of patients with KRAS mutations in 
exon 2; in this subgroup, progression-free sur-
vival in the primary analysis was significantly 
shorter in the panitumumab–FOLFOX4 group 
than in the FOLFOX4-alone group (7.3 months 
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Table 1. RAS and BRAF Mutation Status.*
Variable
Panitumumab–
FOLFOX4
FOLFOX4  
Alone Total
KRAS exon 2 at codons 12 and 13 — no. of patients
Nonmutated 325 331 656
Mutated† 221 219 440
KRAS exon 2 tumors tested for RAS and BRAF 
— no./total no. (%)‡
KRAS exon 3 at codon 61
Nonmutated 308/320 (96) 306/321 (95) 614/641 (96)
Mutated 10/320 (3) 14/321 (4) 24/641 (4)
Not determined 2/320 (1) 1/321 (<1) 3/641 (0)
KRAS exon 4 at codon 117 or 146
Nonmutated 288/320 (90) 296/321 (92) 584/641 (91)
Mutated 21/320 (7) 15/321 (5) 36/641 (6)
Not determined 11/320 (3) 10/321 (3) 21/641 (3)
NRAS exon 2 at codon 12 or 13
Nonmutated 308/320 (96) 307/321 (96) 615/641 (96)
Mutated 8/320 (2) 14/321 (4) 22/641 (3)
Not determined 4/320 (1) 0/321 (0) 4/641 (1)
NRAS exon 3 at codon 61
Nonmutated 305/320 (95) 305/321 (95) 610/641 (95)
Mutated 12/320 (4) 14/321 (4) 26/641 (4)
Not determined 3/320 (1) 2/321 (1) 5/641 (1)
NRAS exon 4 at codon 117 or 146
Nonmutated 316/320 (99) 313/321 (98) 629/641 (98)
Mutated 0/320 (0) 0/321 (0) 0/641 (0)
Not determined 4/320 (1) 8/321 (2) 12/641 (2)
BRAF exon 15 at codon 600
Nonmutated 286/320 (89) 280/321 (87) 566/641 (88)
Mutated 24/320 (8) 29/321 (9) 53/641 (8)
Not determined 10/320 (3) 12/321 (4) 22/641 (3)
All patients who underwent randomization 
— no.
593 590 1183
Ascertainment of mutation status  
— no./total no. (%)
RAS 531/593 (90) 529/590 (90) 1060/1183 (90)§
BRAF 310/593 (52) 309/590 (52) 619/1183 (52)
RAS and BRAF 524/593 (88) 523/590 (89) 1047/1183 (89)¶
* FOLFOX4 denotes oxaliplatin, fluorouracil, and leucovorin.
† A total of 440 patients with KRAS mutations in exon 2 were not retested for RAS or BRAF.
‡ Of 641 samples tested, 2 did not yield a result (and did not have a mutation) in at least one RAS or BRAF exon. Samples 
that had any RAS exon mutation, regardless of whether other RAS exons did not yield a result, were characterized as 
mutant RAS and thus could be evaluated for RAS mutation status.
§ The total includes 440 patients with KRAS mutations in exon 2 and 620 patients with data that could be evaluated for RAS. 
Of 641 samples tested, 21 did not yield a result (and did not have a mutation) in at least one RAS exon.
¶ Of 1060 samples with data that could be evaluated for RAS, an additional 13 did not yield a BRAF result.
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vs. 8.8 months, P = 0.02) (Table 2). In the pri-
mary analysis, interaction testing between the 
subgroups that did not have RAS mutations and 
the subgroups that did not have KRAS mutations 
in exon 2 but did have other RAS mutations was 
significant for progression-free survival (P = 0.04) 
but not for overall survival (P = 0.07). In the up-
dated analysis of overall survival, which was 
based on a larger number of deaths from any 
cause, the results of interaction testing were sig-
nificant (P = 0.01). These results indicate that 
treatment effects differed between the subgroups 
of patients without RAS mutations and those 
without KRAS mutations in exon 2 but with other 
Table 2. Efficacy Results According to RAS Mutation Status.
Variable
Panitumumab– 
FOLFOX4
FOLFOX4  
Alone
Hazard Ratio  
(95% CI)
P  
Value
P Value for  
Interaction Test*
No KRAS mutation in exon 2
No. of patients 325 331
Months of progression-free survival in primary 
 analysis — median (95% CI)
9.6 (9.2–11.1) 8.0 (7.5–9.3) 0.80 (0.66–0.97) 0.02
Months of overall survival — median (95% CI)
Primary analysis 23.9 (20.3–28.3) 19.7 (17.6–22.6) 0.83 (0.67–1.02) 0.07
Updated analysis 23.8 (20.0–27.7) 19.4 (17.4–22.6) 0.83 (0.70–0.98) 0.03
KRAS mutation in exon 2
No. of patients 221 219
Months of progression-free survival in primary 
 analysis — median (95% CI)
7.3 (6.3–8.0) 8.8 (7.7–9.4) 1.29 (1.04–1.62) 0.02
Months of overall survival — median (95% CI)
Primary analysis 15.5 (13.1–17.6) 19.3 (16.5–21.8) 1.24 (0.98–1.57) 0.07
Updated analysis 15.5 (13.1–17.6) 19.2 (16.2–21.5) 1.16 (0.94–1.41) 0.16
No RAS mutation
No. of patients 259 253
Months of progression-free survival in primary 
 analysis — median (95% CI)
10.1 (9.3–12.0) 7.9 (7.2–9.3) 0.72 (0.58–0.90) 0.004
Months of overall survival — median (95% CI)
Primary analysis 26.0 (21.7–30.4) 20.2 (17.7–23.1) 0.78 (0.62–0.99) 0.04
Updated analysis 25.8 (21.7–29.7) 20.2 (17.6–23.6) 0.77 (0.64–0.94) 0.009
No KRAS mutation in exon 2, other RAS mutation
No. of patients 51 57
Months of progression-free survival in primary 
 analysis — median (95% CI)
7.3 (5.3–9.2) 8.0 (6.4–11.3) 1.28 (0.79–2.07) 0.33 0.04
Months of overall survival — median (95% CI)
Primary analysis 17.1 (10.8–19.4) 18.3 (13.0–23.2) 1.29 (0.79–2.10) 0.31  0.07
Updated analysis 17.1 (10.8–19.4) 17.8 (13.0–23.2) 1.39 (0.91–2.13) 0.12 0.01
RAS mutation
No. of patients 272 276
Months of progression-free survival in primary 
 analysis — median (95% CI)
7.3 (6.3–7.9) 8.7 (7.6–9.4) 1.31 (1.07–1.60) 0.008 <0.001
Months of overall survival — median (95% CI)
Primary analysis 15.6 (13.4–17.9) 19.2 (16.7–21.8) 1.25 (1.02–1.55) 0.03 0.004
Updated analysis 15.5 (13.4–17.9) 18.7 (16.5–21.5) 1.21 (1.01–1.45) 0.04 0.001
* The interaction test is for the comparison with nonmutated RAS.
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RAS mutations, suggesting that RAS mutations, 
in addition to KRAS mutations in exon 2, were 
negative predictive factors (Table 2).
In the expanded subgroup of patients with 
mutated RAS tumors, progression-free survival 
(Fig. S3A in the Supplementary Appendix) and 
overall survival (Fig. S3B and S3C in the Supple-
mentary Appendix) were significantly shorter 
in the panitumumab–FOLFOX4 group than in 
the FOLFOX4-alone group in the primary analy-
sis and in the exploratory, updated analysis of 
overall survival. Interaction testing for progres-
sion-free survival and overall survival was sig-
nificant in all data sets, further suggesting that 
RAS mutations had a negative predictive value 
(Table 2). Additional efficacy results for patients 
with data that could not be evaluated for RAS 
are shown in Table S2 in the Supplementary 
Appendix.
The treatment effect on progression-free sur-
vival and overall survival in favor of panitumu mab–
FOLFOX4 in patients with nonmutated RAS was 
observed across subpopulations predefined accord-
ing to baseline covariates, except an ECOG perfor-
mance-status score of 2 (Fig. S4 in the Supplemen-
tary Appendix).
Subsequent to the prespecified analysis, pre-
viously reported mutations in KRAS and NRAS at 
codon 59 (A59G and A59T)9,28-30 were identified 
in seven patients. In an exploratory analysis in-
volving this small patient population, exclusion 
of these mutated alleles slightly improved pro-
gression-free survival and overall survival (Table S3 
and Fig. S5 in the Supplementary Appendix).
Efficacy According to Tumor BRAF Status
In the nonmutated RAS and nonmutated BRAF 
subgroup, panitumumab–FOLFOX4 was associ-
ated with a 1.6-month improvement in progres-
sion-free survival and a 7.4-month improvement 
in overall survival, as compared with FOLFOX4 
alone (Table 3). The minor differences between 
FOLFOX4–panitumumab and FOLFOX4 alone in 
the subgroup of patients without RAS mutations 
but with BRAF mutations were not significant 
(Fig. S6 in the Supplementary Appendix).
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Figure 1. Hazard Ratio for Disease Progression or Death and Hazard Ratio for Death from Any Cause, According to 
KRAS and RAS Mutation Status.
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Figure 2. Kaplan–Meier Estimates of Progression-free Survival in the Primary-Analysis Population and Overall Survival in the Primary-
Analysis and Updated-Analysis Populations, According to Treatment Group.
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Prognostic Effects of RAS and BRAF Mutation 
Status
The prognostic effects of RAS and BRAF mutation 
status were evaluated by comparing the hazard 
ratios for death from any cause with no mutation 
versus mutation within each treatment group 
and across groups (Fig. S7 in the Supplementary 
Appendix). Most hazard ratios favored nonmu-
tated status in the panitumumab–FOLFOX4 
group and were neutral in the FOLFOX4-alone 
group. BRAF mutations were associated with re-
duced overall survival among patients without 
KRAS mutations in exon 2 and among those with 
NRAS mutations in exon 3.
Safety
The incidence rates, types, and severity of adverse 
events among patients with nonmutated RAS in 
the panitumumab–FOLFOX4 group (Table 4) were 
similar to those previously reported in the group 
of patients with nonmutated KRAS exon 2 who 
were treated with panitumumab–FOLFOX4.2 Treat-
ment exposure, disease-control rates, and the pro-
portion of patients who discontinued any study 
drug due to an adverse event were also similar to 
those previously reported.2 The safety profile for 
patients with RAS mutations was similar to that re-
ported for patients with KRAS mutations in exon 2. 
No new safety signals were identified.
Discussion
Testing for KRAS exon 2 tumor mutations is cur-
rently recommended to help guide decisions re-
garding eligibility for anti-EGFR therapy in pa-
tients with metastatic colorectal cancer. Although 
KRAS testing has facilitated the selection of pa-
tients who are most likely to have a response to 
anti-EGFR therapy, a substantial fraction of pa-
tients do not benefit from treatment. It is hoped 
Table 3. Efficacy Results According to RAS and BRAF Mutation Status in the Primary-Analysis Population.*
Variable
Panitumumab–
FOLFOX4
FOLFOX4  
Alone
Hazard Ratio  
(95% CI)
P  
Value
No RAS or BRAF mutations
No. of patients 228 218
Months of progression-free survival  
— median (95% CI)
10.8 (9.4–12.4) 9.2 (7.4–9.6) 0.68 (0.54–0.87) 0.002
Months of overall survival  
— median (95% CI)
28.3 (23.7–NE) 20.9 (18.4–23.8) 0.74 (0.57–0.96) 0.02
No RAS mutation, BRAF mutation
No. of patients 24 29
Months of progression-free survival  
— median (95% CI)
6.1 (3.7–10.7) 5.4 (3.3–6.2) 0.58 (0.29–1.15) 0.12
Months of overall survival  
— median (95% CI)
10.5 (6.4–18.9) 9.2 (8.0–15.7) 0.90 (0.46–1.76) 0.76
RAS or BRAF mutation
No. of patients 296 305
Months of progression-free survival 
 — median (95% CI)
7.3 (6.3–7.7) 8.0 (7.5–9.0) 1.24 (1.02–1.49) 0.03
Months of overall survival  
— median (95% CI)
15.3 (12.7–17.6) 18.0 (15.9–20.8) 1.21 (0.99–1.47) 0.06
No KRAS mutation in exon 2, other RAS 
or BRAF mutation
No. of patients 75 86
Months of progression-free survival  
— median (95% CI)
6.7 (5.3–8.2) 7.3 (5.7–8.0) 1.05 (0.73–1.52) 0.80
Months of overall survival  
— median (95% CI)
14.5 (10.4–18.5) 15.8 (11.9–18.8) 1.14 (0.78–1.66) 0.51
* NE denotes not evaluated.
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that further refinement of tumor-specific genetic 
markers will allow more accurate selection of pa-
tients who are likely to have a response to a par-
ticular treatment and prevent toxic effects in those 
who are unlikely to benefit.
Biomarker exploration has been broadened 
to include EGFR pathway mutations, in addition 
to those in KRAS exon 2. In a retrospective bio-
marker analysis of a randomized phase 3 study 
of panitumumab monotherapy, EGFR signaling–
pathway genes were assessed for their predictive 
ability.10 From this study, a hypothesis was gener-
ated that activating mutations in KRAS or NRAS 
would be predictive of nonresponse to panitum-
umab therapy. The current analysis, which was 
based on biologic plausibility and exploratory bio-
marker data, further assesses the hypothesis that 
additional activating RAS mutations predict unre-
sponsiveness to panitumumab treatment.7,10,21,28
Negative treatment effects of panitumumab–
FOLFOX4 on progression-free survival and over-
all survival were observed among patients with 
tumors that did not have KRAS mutations in 
exon 2 but that did have other RAS mutations. In 
an interaction test, treatment effects were sig-
nificantly worse than those in the group of pa-
tients with nonmutated RAS; this suggests that 
mutations in RAS, in addition to KRAS mutations 
in exon 2, are predictive of adverse outcomes for 
panitumumab–FOLFOX4 treatment. The magni-
tude of the treatment effect in the patients with 
mutated RAS was similar to that previously ob-
served in patients with mutated KRAS exon 22 
and further indicated that patients with tumors 
that harbored any activating RAS mutations did 
not benefit from and may have been harmed by 
panitumumab–FOLFOX4 treatment.
Among patients in the primary-analysis popu-
lation who did not have RAS mutations, an in-
crease in overall survival of 5.8 months was noted 
with the addition of panitumumab to FOLFOX4 
as compared with FOLFOX4 alone. The results of 
the exploratory, updated analysis of overall sur-
vival were consistent with these findings. The ob-
served incidence, types, and severity of adverse 
events associated with panitumumab–FOLFOX4 
in the nonmutated RAS and mutated RAS sub-
groups were similar to the previously reported 
safety findings for KRAS in PRIME,2 and no 
new safety signals were identified.
In the subgroup of patients without RAS and 
BRAF mutations, a 7.4-month increase in overall 
survival was observed in the panitumumab–
FOLFOX4 group. As suggested previously,17 BRAF 
V600E mutations appeared to confer a poor prog-
nosis, regardless of the treatment group.
This analysis was retrospective and explorato-
ry in nature and therefore subject to limitations. 
The alpha error for hypothesis testing was previ-
ously allocated to the primary analysis,2 and RAS 
and BRAF status may not be representative of the 
intention-to-treat population from the original 
Table 4. Summary of Adverse Events, According to RAS Mutation Status in the Primary-Analysis Population.
Adverse Event Nonmutated RAS Mutated RAS
Panitumumab–
FOLFOX4 
(N = 256)
FOLFOX4 
Alone 
(N = 250)
Total 
(N = 506)
Panitumumab–
FOLFOX4 
(N = 268)
FOLFOX4 
Alone 
(N = 275)
Total 
(N = 543)
number of patients (percent)
Any adverse event 256 (100) 248 (99) 504 (100) 266 (99) 273 (99) 539 (99)
Worst grade of 3 146 (57) 124 (50) 270 (53) 153 (57) 146 (53) 299 (55)
Worst grade of 4 71 (28) 51 (20) 122 (24) 63 (24) 55 (20) 118 (22)
Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)
Any serious adverse event 110 (43) 92 (37) 202 (40) 121 (45) 84 (31) 205 (38)
Adverse event leading to per-
manent discontinuation of 
any study drug
65 (25) 40 (16) 105 (21) 60 (22) 37 (13) 97 (18)
Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)
Serious 24 (9) 15 (6) 39 (8) 17 (6) 14 (5) 31 (6)
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randomization. However, methodologic aspects 
of the analysis provided a rigorous framework for 
evaluating RAS and BRAF as biomarkers. Tissue 
samples were collected with appropriate informed 
consent before randomization. The biomarker 
hypothesis was restricted to RAS and BRAF, and 
the statistical analysis plan was finalized before 
RAS and BRAF status became available. In addi-
tion, the analysis was conducted with data from a 
large, randomized, controlled trial.2 The high 
rate of ascertainment of RAS status (90%) mini-
mized the potential for ascertainment bias. Two 
laboratory-developed tests, validated according 
to the Clinical Laboratory Improvement Amend-
ments of 1988, provided mutual confirmation.
Two interaction tests showed a clear separa-
tion of panitumumab treatment effects between 
nonmutated RAS and mutated RAS as well as 
between nonmutated RAS and nonmutated KRAS 
exon 2 with other RAS mutations; the latter find-
ing indicates the predictive value of RAS muta-
tions other than KRAS mutations in exon 2. These 
results were observed across all meaningful end 
points and in all relevant subgroups.
In conclusion, RAS mutations, in addition to 
KRAS exon 2 mutations, predict a lack of re-
sponse to anti-EGFR therapy in patients with 
metastatic colorectal cancer. Panitumumab plus 
oxaliplatin-containing regimens have no value 
in patients with metastatic colorectal cancer 
and mutated RAS. The benefit–risk profile of 
panitumumab–FOLFOX4 was improved by ex-
cluding patients with mutated RAS metastatic 
colorectal-cancer tumors. Pooled trials or meta-
analyses of anti-EGFR therapy are needed to 
confirm these findings.
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